Title : Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1.

Pub. Date : 2019 Apr 18

PMID : 30995372






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1. Busulfan interleukin 2 receptor subunit gamma Homo sapiens
2 CONCLUSIONS: Lentiviral vector gene therapy combined with low-exposure, targeted busulfan conditioning in infants with newly diagnosed SCID-X1 had low-grade acute toxic effects and resulted in multilineage engraftment of transduced cells, reconstitution of functional T cells and B cells, and normalization of NK-cell counts during a median follow-up of 16 months. Busulfan interleukin 2 receptor subunit gamma Homo sapiens